Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

1.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

571
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
571
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

775
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
775
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

8.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polystyrene nanoplastics impair epithelial barrier establishment and modulate extracellular vesicle release in human bronchial cells cultured at the air-liquid interface.

Toxicology·2026
Same author

Micro-Nanoplastic Exposure and Lung Cancer Biomarkers: The Role of Extracellular Vesicle-Mediated Intercellular Communication.

International journal of molecular sciences·2026
Same author

The crucial role of thromboxane A<sub>2</sub> in colorectal cancer development and metastasis: a key target for anticancer therapy.

Frontiers in pharmacology·2026
Same author

Flow Cytometry Role in Unlocking New Frontiers for Nanomedicine Applications of Plant-Derived Vesicles.

Journal of extracellular biology·2026
Same author

Vapor Deposited Metal Halide Perovskites for Photovoltaics: Methods, Challenges and Prospects.

Chemical reviews·2026
Same author

Intestinal Protective Effects of a Pomegranate Peel Extract in In Vitro and Ex Vivo Studies.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jul 29, 2025

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

724

Cyclooxygenases and platelet functions.

Annalisa Bruno1, Stefania Tacconelli1, Annalisa Contursi1

  • 1Center for Advanced Studies and Technology (CAST), Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Chieti, Italy.

Advances in Pharmacology (San Diego, Calif.)
|May 26, 2023
PubMed
Summary

Low-dose aspirin selectively inhibits platelet cyclooxygenase-1 (COX-1), reducing thromboxane A2 (TXA2) production. This inhibition prevents cyclooxygenase-2 (COX-2) induction, offering antifibrotic and antitumor benefits in chronic inflammation.

Keywords:
AtherothrombosisCancerCyclooxygenaseEicosanoidsFibrosisInflammationLow-dose aspirinPlateletsThromboxane A(2)

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:01

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

200
In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

10.8K

Related Experiment Videos

Last Updated: Jul 29, 2025

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

724
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:01

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

200
In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

10.8K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Cyclooxygenase (COX) enzymes, COX-1 and COX-2, produce prostaglandins from arachidonic acid.
  • Platelets primarily express COX-1, generating thromboxane A2 (TXA2), a key mediator in atherothrombosis and inflammation.
  • COX-2 is induced during inflammation, producing PGE2 and PGI2, while PGI2 also has protective cardiovascular functions.

Purpose of the Study:

  • To describe the role of platelets in regulating COX-2 expression within the inflammatory microenvironment.
  • To highlight the therapeutic potential of selective COX-1 inhibition in managing inflammatory diseases.

Main Methods:

  • Review of existing literature on COX isozymes, prostanoid biosynthesis, and platelet function.
  • Analysis of the molecular mechanisms linking platelet TXA2 to COX-2 induction.
  • Discussion of therapeutic strategies targeting platelet prostanoid pathways.

Main Results:

  • Selective inhibition of platelet COX-1 by low-dose aspirin prevents COX-2 induction in stromal cells.
  • This mechanism underlies the observed antifibrotic and antitumor effects of aspirin in inflammatory conditions.
  • Platelets significantly influence the inflammatory microenvironment through TXA2 signaling.

Conclusions:

  • Targeting platelet COX-1 offers a promising strategy for treating chronic inflammatory diseases.
  • Low-dose aspirin's benefits extend beyond antiplatelet effects to include modulation of inflammatory responses.
  • Further research into prostanoid receptors and synthases could yield novel anti-inflammatory therapies.